Haibu Pharmaceutical has completed a financing of 40 million yuan, creating a chemical pharmaceutical research and development company centered on technological research and development, covering the entire industry chain.

　　Recently, Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as "Haibu Pharmaceutical") announced the completion of a financing round totaling 40 million yuan. This financing was provided by Shenzhen Tongchuang Weiye Asset Management Co., Ltd. The funds raised will mainly be used for innovative drug discovery and incubation, generic drug development, expansion of domestic and international raw material business, establishment of clinical trial research platforms, construction of drug R&D software and hardware, and talent team building.

　　Founded in 2005, Haibu Pharmaceutical is a high-tech enterprise focused on the research and development of chemical drugs. It mainly engages in the R&D, production, sales of chemical raw materials, pharmaceutical intermediates, and drug formulations as well as technology transfer and technical services. Haibu Pharmaceutical has consistently focused on chemical drug R&D and has stood out among numerous drug R&D companies, growing into a leading domestic enterprise in drug formulation technology development and technical services as well as a leading company in the R&D and sales of raw materials and intermediates.

　　By the end of 2017, Haibu Pharmaceutical had provided high-quality intermediates and raw material products to nearly 100 domestic and foreign pharmaceutical companies including Shiyao Group, Jiangsu Hengrui Medicine, Haizheng Pharmaceutical, MSN, Hetero, Sun Pharma among others; it also provided over 100 technology transfer and technical services for domestic pharmaceutical companies.

　　Haibu Pharmaceutical closely follows international pharmaceutical development trends while adapting to national policy adjustments. It continuously enhances its technological R&D capabilities by optimizing drug R&D processes and strengthening data information construction to ensure the scientificity and standardization of drug R&D. The technological development in pharmaceuticals has achieved leapfrog progress. Haibu Pharmaceutical meticulously focuses on the details of pharmaceutical research technology while attempting collaboration in critical areas such as bioequivalence to verify the quality and efficacy of generic drugs. This allows for comprehensive control over the entire chain of consistency evaluation to strictly ensure the quality and efficacy of generic drugs; based on strengthening generic drug development, Haibu is committed to creating innovative drug pipelines in areas such as mental health disorders and anti-tumor therapies through various models including independent research & development and collaborative development to enhance its innovation capabilities; it actively applies cutting-edge chemical transformation technologies and synthesis processes such as enzyme catalysis technology and continuous flow reaction technology in raw material production to improve production efficiency, reduce costs while meeting green chemistry requirements.

　　Liu Changru, founder and chairman of Haibu Pharmaceutical stated: "Haibu Pharmaceutical focuses on R&D and technology at its core within the field of chemical drugs. Drug research is a rigorous scientific practice that is complex, time-consuming, labor-intensive; it tests our talents as well as our willpower and collaborative abilities. Every task we undertake plays a crucial role in ensuring the safety, effectiveness, cost-effectiveness, and pricing of medicines. Every researcher at Haibu must approach their work with reverence for life; during every stage of research & development they must adhere to a spirit that values scientific rigor while being pragmatic—striving for perfection in both technology and products."

　　When discussing this financing round Liu Changru remarked: "We are honored to receive attention from investors; we are even more fortunate to have Tongchuang Weiye's high praise for Haibu's steady growth over more than a decade since its establishment. In an era characterized by rapid technological advancement alongside swift market changes where new technologies, methods models emerge constantly—Haibu must maintain an open mindset with broad thinking while proactively innovating seeking change rapidly converting technologies into products efficiently with efforts from all employees supported by capital assistance achieving profitability reflecting company value. This financing supported by Tongchuang Weiye will greatly promote Haibu's rapid growth according to strategic layout pushing our business development to new heights."

　　Haibu Pharmaceutical from an investor's perspective

　　Xie Yanbin, Investment Director at Tongchuang Weiye believes: "Haibu Pharmaceutical possesses a high-level R&D team along with a strict scientific management system diversified service system international vision for development. The platform holds value willing to accompany support its growth together promoting the advancement of China's chemical pharmaceutical industry earning trust respect from patients doctors society."

　　About Haibu Pharmaceutical

　　Beijing Haibu Pharmaceutical Technology Co., Ltd. (stock abbreviation: Haibu Pharmaceutical; stock code: 836438) was established in Beijing Economic-Technological Development Area in 2005 focusing on global high-tech enterprises centered around chemical drug research & development. The company primarily engages in R&D production sales technology transfer technical services related to chemical raw materials pharmaceutical intermediates drug formulations owning two wholly-owned subsidiaries Beijing Haimaitong Beijing Haimaiyuan.

　　Haibu Pharmaceutical has over 4,000 square meters laboratory nearly a team comprising about 200 researchers with those holding master's degrees or above accounting for 32%. It is equipped with conventional instruments related to chemical synthesis formulation analysis along with high-end equipment ranging from small-scale trials up through pilot scale providing ample assurance for high-quality research work across multiple fields including anti-tumor depression cardiovascular digestive respiratory medications achieving numerous research results.

　　About Tongchuang Weiye

　　Tongchuang Weiye is one of China's first professional private equity investment firms boasting seventeen years' experience asset management scale ranking among industry leaders focusing long-term investments startup enterprises being one domestically leading institutions operating long time yielding consistently excellent returns.